Skip to main content
. 2025 Aug 8;15:1608664. doi: 10.3389/fonc.2025.1608664

Table 2.

Clinicopathological and molecular characteristics of RNF43 codon 659-mutated and RNF43 Non-codon 659-mutated.

Clinicopathologic characteristics Number of patients, N (%) (N=282) RNF43 codon 659-mutated, N (%) (N=118) RNF43 Non-codon 659-mutated, N (%) (N=164) P value
Age (median 57.94, range 13–95) 0.2249
Young (years <50) 83 (29.43%) 30 (25.42%) 53 (32.32%)
Intermediate (<70 years ≥50) 103 (36.52%) 41 (34.75%) 62 (37.80%)
Elder (years≥70) 95 (33.69%) 46 (38.98%) 49 (29.88%)
NA 1 (0.35%) 1 (0.85%) 0 (0.00%)
Gender 0.1343
Female 149 (52.84%) 60 (50.85%) 89 (54.27%)
Male 118 (41.84%) 48 (40.68%) 70 (42.68%)
NA 15 (5.32%) 10 (8.47%) 5 (3.05%)
Primary tumor location <0.0001
Right 147 (52.13%) 70 (59.32%) 77 (46.95%)
Left 69 (24.47%) 13 (11.02%) 56 (34.15%)
NA 66 (23.40%) 35 (29.66%) 31 (18.90%)
TNM stage 0.0124
I 38 (13.48%) 12 (10.17%) 26 (15.85%)
II 91 (32.27%) 43 (36.44%) 48 (29.27%)
III 77 (27.30%) 35 (29.66%) 42 (25.61%)
IV 56 (19.86%) 15 (12.71%) 41 (25.00%)
NA 20 (7.09%) 13 (11.02%) 7 (4.27%)
TUMOR_GRADE
Well differentiated 45 (15.96%) 14 (11.86%) 31 (18.90%) 0.0196
Moderately differentiated 63 (22.34%) 19 (16.10%) 44 (26.83%)
Moderate poorly differentiated 10 (3.55%) 3 (2.54%) 7 (4.27%)
Poorly differentiated 58 (20.57%) 26 (22.03%) 32 (19.51%)
NA 106 (37.59%) 56 (47.46%) 50 (30.49%)
TMB <0.0001
TMB-H 198 (70.21%) 110 (93.22%) 88 (53.66%)
TMB-L 67 (23.76%) 2 (1.69%) 65 (39.63%)
NA 17 (6.03%) 6 (5.08%) 11 (6.71%)
MSI <0.0001
MSI-H 138 (48.94%) 93 (78.81%) 45 (27.44%)
MSS 92 (32.62%) 2 (1.69%) 90 (54.88%)
NA 52 (18.44%) 23 (19.49%) 29 (17.68%)
BRAF status 0.2519
BRAF mut 96 (34.04%) 45 (38.14%) 51 (31.10%)
BRAF wild-type 186 (65.96%) 73 (61.86%) 113 (68.90%)
BRAF mutation types 0.3272
Class 1 86 (30.50%) 42 (35.59%) 44 (26.83%)
Class 2 0 (0.00%) 0 (0.00%) 0 (0.00%)
Class 3 0 (0.00%) 0 (0.00%) 0 (0.00%)
NA 10 (3.55%) 3 (2.54%) 7 (4.27%)